- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07948278
15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)
A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years
This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.
Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ting Wu
- Numéro de téléphone: 0592-2880621
- E-mail: wuting.@xmu.edu.cn
Lieux d'étude
-
-
Guangxi
-
Liuzhou, Guangxi, Chine, 545007
- Liuzhou Center for Disease Control and Prevention
-
Contact:
- Haibo Wang, MSc
- Numéro de téléphone: +86-772-3720738
- E-mail: lzcdcxmb@163.com
-
-
Hebei
-
Fengning, Hebei, Chine, 068350
- Fengning Hospital of Traditional Chinese Medicine
-
Contact:
- Cuihong Dai, BSc
- Numéro de téléphone: +86-314-8080327
- E-mail: wxn_cdfn@126.com
-
-
Henan
-
Qingpingjie, Henan, Chine, 452370
- Xinmi Maternal and Child Health Hospital
-
Contact:
- Fengxian Zheng, BSc
- Numéro de téléphone: +86-371-69833851
- E-mail: 513940819@qq.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).
La description
Inclusion Criteria:
- The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
- The participant has given informed consent and signed the consent form.
- The participant is able to complete all study procedures as required by the protocol.
Exclusion Criteria:
- Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
- The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
- In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Vaccine group
Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant |
|
Control group
Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Délai: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Délai: At months 156 and 180 after the first dose in the original trial
|
Infection with the same HPV type must persist for at least 6 months |
At months 156 and 180 after the first dose in the original trial
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Délai: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
CIN2+ associated with HPV type 16 or 18
Délai: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Délai: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-16-specific infection and/or lesion endpoints
Délai: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-18-specific infection and/or lesion endpoints
Délai: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Délai: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Délai: At months 156 and 180 after the first dose in the original trial
|
Percentage of participants seropositive for HPV-16 and HPV-18 antibodies |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific HPV-16 and HPV-18 antibody levels
Délai: At months 156 and 180 after the first dose in the original trial
|
Serum antibody titers against HPV-16 and HPV-18 |
At months 156 and 180 after the first dose in the original trial
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
incident HPV-16 and/or HPV-18 infection
Délai: At months 156 and 180 after the first dose in the original trial
|
Newly detected HPV-16 and/or HPV-18 DNA positivity |
At months 156 and 180 after the first dose in the original trial
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Jun Zhang, Xiamen University
- Chercheur principal: Ting Wu, Xiamen University
Publications et liens utiles
Publications générales
- Zhao F, Chen Q, Zhao C, Nie L, Hu S, Yin J, Qiu L, Bi Z, Quan J, Li Y, Li M, Zhang X, Pan Q, Li C, Ke L, Liu X, Zheng F, Dai C, Wang Z, Kuang X, Jia X, Su Y, Huang S, Zhang Q, Huang W, Wei L, Zhang J, Wu T, Qiao Y, Xia N. Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. Lancet Reg Health West Pac. 2025 Aug 21;61:101668. doi: 10.1016/j.lanwpc.2025.101668. eCollection 2025 Aug.
- Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26.
- Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J, Xia NS. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153. doi: 10.1093/jnci/djz074.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Processus pathologiques
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Attributs de la maladie
- Infections
- Maladies utérines
- Maladies génitales, femme
- Conditions précancéreuses
- Maladies du col de l'utérus
- Conditions pathologiques, signes et symptômes
- Infection persistante
- Dysplasie cervicale utérine
- Produits biologiques
- Mélanges complexes
- Vaccins
Autres numéros d'identification d'étude
- HPV-PRO-003-4
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .